Ann: Chair Elect Letter, page-11

Almost certainly no trials. I only reference this as in the December 22 newsletter Wolgen unambiguously stated that 23 would see the “first results of parvys, phimelanotide as novel molecules used for topical applications.”

But remember the dismal share price is due to shorters and global events and nothing to do with hopeless execution and consistent failure to hit any timeline. The number one priority should clearly be retention of current management given they have done such a fantastic job of growing the company in the last 4 years.